Last reviewed · How we verify

Celebrex — Competitive Intelligence Brief

Celebrex (celecoxib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal Anti-inflammatory Drug [EPC]. Area: Immunology.

marketed Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Celebrex (celecoxib) — Pfizer Inc. (originally Searle/Pharmacia). Celecoxib works by inhibiting COX-2 to reduce prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Celebrex TARGET celecoxib Pfizer Inc. (originally Searle/Pharmacia) marketed Nonsteroidal Anti-inflammatory Drug [EPC] COX-2 1998-12-31
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Ibuprofen + Paracetamol Ibuprofen + Paracetamol Ullevaal University Hospital marketed Fixed-dose combination of NSAID and analgesic/antipyretic COX-1/COX-2 (ibuprofen); central nervous system analgesic/antipyretic pathways (paracetamol)
Etoricoxib (Arcoxia) Etoricoxib (Arcoxia) Radboud University Medical Center marketed Selective COX-2 inhibitor (coxib) COX-2 (Cyclooxygenase-2)
Aspirin (acetylsalicylic acid) Aspirin (acetylsalicylic acid) Swedish Medical Center marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen + Pseudoephedrine Hydrochloride Ibuprofen + Pseudoephedrine Hydrochloride Dr. Reddy's Laboratories Limited marketed NSAID + decongestant combination COX-1/COX-2 (ibuprofen); alpha-adrenergic receptors (pseudoephedrine)
Ibuprofen Acid Ibuprofen Acid Reckitt Benckiser Healthcare (UK) Limited marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Nonsteroidal Anti-inflammatory Drug [EPC] class)

  1. · 8 drugs in this class
  2. Pfizer · 2 drugs in this class
  3. Assiut University · 1 drug in this class
  4. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
  5. Centro Hospitalar Lisboa Ocidental · 1 drug in this class
  6. Dartmouth-Hitchcock Medical Center · 1 drug in this class
  7. Dr. Vishwanath Karad MIT World Peace University · 1 drug in this class
  8. Dr. Reddy's Laboratories Limited · 1 drug in this class
  9. Generic (originally Boots Group) · 1 drug in this class
  10. Boehringer Ingelheim · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celebrex — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: